WebMD Global requires every individual in a position to control educational content to disclose all financial relationships
with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary
business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed
below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with
ineligible companies.
Faculty

-
Barbara K. Burton, MD
Professor of Pediatrics
Northwestern University Feinberg School of Medicine
Attending Physician
Division of Genetics, Birth Defects and Metabolism
Ann and Robert H. Lurie Children's Hospital
Chicago, Illinois
Disclosures
Disclosure: Barbara K. Burton, MD, has the following relevant financial relationships:
Served as an advisor or consultant for: Aeglea BioTherapeutics; Alexion Pharmaceuticals, Inc.; Applied Therapeutics; BioMarin
Pharmaceutical Inc; Denali Therapeutics; Genzyme; Horizon Pharma; JCR Pharmaceuticals; Moderna, Inc.; Orchard Therapeutics;
Passage Bio; Sio Gene Therapies; Takeda; Ultragenyx
Served as a speaker or a member of a speakers bureau for: BioMarin Pharmaceutical Inc; Takeda
Received grants for clinical research from: BioMarin Pharmaceutical Inc; Denali Therapeutics; Homology Medicines; JCR Pharmaceuticals;
Sangamo BioSciences, Inc.; Takeda; Ultragenyx

-
Klane K. White, MD, MSc
Director
Skeletal Health and Dysplasia Program
Medical Director
Orthopaedic Research
Professor
Orthopedics and Sports Medicine
Seattle Children's Hospital
University of Washington
Seattle, Washington, United States
Disclosures
Disclosure: Klane K. White, MD, MSc, has the following relevant financial relationships:
Served as an advisor or consultant for: BioMarin Pharmaceutical Inc
Served as a speaker or a member of a speakers bureau for: BioMarin Pharmaceutical Inc
Received grants for clinical research from: BioMarin Pharmaceutical Inc; Pfizer, Inc.; TherAchon; Ultragenyx
Editor
Compliance Reviewer